Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H34N4O5S |
| Molecular Weight | 490.616 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@@H]3CC[C@H](C)CC3)C1=O
InChI
InChIKey=WIGIZIANZCJQQY-UWUNEBHHSA-N
InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19+
| Molecular Formula | C24H34N4O5S |
| Molecular Weight | 490.616 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Prevention of weight gain in type 2 diabetes requiring insulin treatment. | 2004-03 |
|
| Long-acting sulfonylureas -- long-acting hypoglycaemia. | 2004-01-19 |
|
| Determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. | 2004-01-05 |
|
| Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. | 2004-01 |
|
| Protective actions of gliclazide on high insulin-enhanced neutrophil-endothelial cell interactions through inhibition of mitogen activated protein kinase and protein kinase C pathways. | 2004-01 |
|
| The influence of glimepiride on the binding kinetics of insulin with its skeletal muscle and liver receptors in rats with short term and prolonged hyperglycemia induced by streptozotocin. | 2004-01 |
|
| Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity. | 2004-01 |
|
| Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy. | 2003-12 |
|
| Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al. | 2003-12 |
|
| Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. | 2003-12 |
|
| Study of glimepiride-b-cyclodextrin complex. | 2003-11 |
|
| Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride. | 2003-11 |
|
| The influence of glimepiride on the oxidative state of rats with streptozotocin-induced hyperglycemia. | 2003-11 |
|
| Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. | 2003-11 |
|
| Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. | 2003-10-30 |
|
| A diabetic woman with worsening heart failure, hunger, and tremor. | 2003-10 |
|
| Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. | 2003-10 |
|
| Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. | 2003-08 |
|
| Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study. | 2003-07 |
|
| Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. | 2003-07 |
|
| Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B. | 2003-07 |
|
| Summaries for patients. A comparison of three insulin regimens (morning glargine, bedtime glargine, or bedtime neutral protamine Hagedorn) in addition to a pill for treating type 2 diabetes. | 2003-06-17 |
|
| Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. | 2003-06-17 |
|
| Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. | 2003-06 |
|
| Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. | 2003-06 |
|
| Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study. | 2003-06 |
|
| Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. | 2003-06 |
|
| Pitfalls in endosonographic imaging of suspected insulinomas: pancreatic nodules of unknown dignity. | 2003-05 |
|
| Combined bedtime insulin--daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate--a randomised trial. | 2003-04-04 |
|
| Glimepiride treatment and IGF-I in adolescents with type 1 diabetes: a prospective, randomized, double-blind, placebo-controlled study. | 2003-04 |
|
| [Differences between oral antidiabetics]. | 2003-03-20 |
|
| Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. | 2003-03-08 |
|
| Effects of sulfonylureas on K(ATP) channel-dependent vasodilation. | 2003-03-08 |
|
| Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. | 2003-03 |
|
| The mechanisms underlying the unique pharmacodynamics of nateglinide. | 2003-03 |
|
| Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. | 2003-02 |
|
| Differential effects of sulphonylureas on the vasodilatory response evoked by K(ATP) channel openers. | 2003-02 |
|
| Impairment of myocardial protection in type 2 diabetic patients. | 2003-02 |
|
| Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. | 2003-01 |
|
| [Glimepiride in daily practice]. | 2003 |
|
| [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]. | 2003 |
|
| A flaw in the use of sulfonylurea screening to diagnose sulfonylurea overdosages. | 2003 |
|
| Inadvertent sulfonylurea overdosage and hypoglycemia in an elderly woman: failure of serum hypoglycemia screening. | 2003 |
|
| [Glimepiride--an oral antidiabetic agent]. | 2003 |
|
| [Sulfonylurea receptors and their interaction with glimepiride]. | 2003 |
|
| [Fear of the injection must not be an argument. Every second type 2 diabetic patient needs insulin]. | 2002-12-05 |
|
| [Molecular mechanisms of insulin secretion]. | 2002-12 |
|
| Immunoreactive insulin response to a single dose of glimepiride in lean type 2 diabetic subjects. | 2002-10 |
|
| Amaryl (glimepiride) in patients with type 2 diabetes mellitus. | 2002 |
|
| [Progress in studies on antidiabetic agents]. | 2001-09 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:49:23 GMT 2025
by
admin
on
Mon Mar 31 21:49:23 GMT 2025
|
| Record UNII |
24T6XIR2MZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
684286-46-2
Created by
admin on Mon Mar 31 21:49:23 GMT 2025 , Edited by admin on Mon Mar 31 21:49:23 GMT 2025
|
PRIMARY | |||
|
1292314
Created by
admin on Mon Mar 31 21:49:23 GMT 2025 , Edited by admin on Mon Mar 31 21:49:23 GMT 2025
|
PRIMARY | |||
|
24T6XIR2MZ
Created by
admin on Mon Mar 31 21:49:23 GMT 2025 , Edited by admin on Mon Mar 31 21:49:23 GMT 2025
|
PRIMARY | |||
|
3476
Created by
admin on Mon Mar 31 21:49:23 GMT 2025 , Edited by admin on Mon Mar 31 21:49:23 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
